- RecruitingPHASE3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
This study looks at a new treatment combination for a type of advanced lung cancer called extensive stage small-cell lung cancer (ES-SCLC). It compares a combination including tarlatamab with a standard treatment to see if it helps people live longer.
For: Small-cell Lung Cancer · Extensive Stage Small-cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
This study looks at a new way to treat certain head, neck, and throat cancers. It combines a drug called durvalumab with a different type of radiation therapy. The aim is to see if this new approach controls cancer just as well as standard treatment, with fewer side effects.
For: HNSCCFrance - Active not recruitingPHASE2
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
This study looks at new drug combinations (Durvalumab and Tremelimumab with FOLFIRI chemotherapy) for advanced stomach or food pipe cancer that has already been treated. It aims to see how well patients respond and if these combinations can help people live longer.
For: Gastric Adenocarcinoma · Gastric CancerFrance - RecruitingPHASE1, PHASE2
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This study is testing a new drug, IDE849, for certain cancers including a type of lung cancer. It aims to see if it's safe and effective, sometimes using it alone and sometimes with other medicines.
For: Small-cell Lung Cancer · Neuroendocrine Carcinomas · Solid Tumor Show to Express DLL3United States · Australia · Brazil - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - Active not recruitingPHASE2
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
This study is for women with a certain type of breast cancer (Luminal B). It tests new ways to combine chemotherapy, radiation, and new drugs (durvalumab and oleclumab) before surgery to see if they work better at treating the cancer.
For: Luminal BBelgium · France - RecruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - Active not recruitingPHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This study looks at a new drug, durvalumab, and standard chemotherapy (FLOT) for stomach or food pipe cancer that can be removed by surgery. It aims to see if this combination, given before and after the operation, is safe and effective.
For: Gastrointestinal Neoplasms · Esophagogastric JunctionUnited States · Argentina · Belgium - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
This study, called DURANCE, is testing a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a vaccine (S-488210/S-488211) with an immunotherapy drug (durvalumab) to see if it's safe and effective in people who haven't responded well to previous treatments.
For: Bladder CancerUnited Kingdom - Active not recruitingPHASE3
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
This study is looking at a new drug called durvalumab, combined with standard chemotherapy, for people with advanced bile duct cancer. It aims to see if this combination is safe and works better than current treatments in shrinking tumours and improving health.
For: Biliary Tract CancerUnited States · France · Germany - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
For: Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · MethotrexateAustralia · Brazil · Canada - Active not recruitingPHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat a type of lung cancer that can be removed by surgery. It combines standard chemotherapy with a new immunotherapy drug (durvalumab) and different types of radiation therapy to see if this mix works better.
For: Non-small Cell Lung Cancer · NSCLCGermany · Switzerland - Active not recruitingPHASE2
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
This study looks at new ways to treat a type of throat cancer called oropharyngeal squamous cell carcinoma, linked to HPV. It compares standard radiotherapy and chemotherapy with newer immunotherapy drugs, durvalumab and tremelimumab, to see if they can work better at stopping the cancer from coming back.
For: Oropharyngeal Squamous Cell CarcinomaBelgium · Canada · Italy - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
This study is for people with certain types of non-small cell lung cancer. It tests a new approach using a drug called durvalumab with chemotherapy, followed by either surgery or other treatments. The aim is to see how well it works and if it's safe.
For: Non-small Cell Lung CancerUnited States · Austria · Canada - Active not recruitingPHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This study is testing different combinations of new drugs (olaparib, durvalumab, capivasertib, and cediranib) for recurrent or hard-to-treat womb cancer. The aim is to find out if these combinations can stop the cancer from growing or spreading more effectively.
For: Endometrial Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous AdenocarcinomaUnited States · Canada - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
For: Pancreatic Cancer · Hepatocellular Cancer · Biliary Tract CancerCanada - Active not recruitingPHASE2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
This study is looking at a new combination of medicines - AZD0171, durvalumab, and standard chemotherapy - for people with advanced pancreatic cancer. It aims to see how safe and effective this new treatment is.
For: Locally Advanced or Metastatic Solid TumoursUnited States · Canada · South Korea - Active not recruiting
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
This study looks at how a new drug, durvalumab, works for people with a serious type of lung cancer called extensive stage small cell lung cancer. It checks its real-world benefits and safety outside of strict trial conditions in France.
For: Small Cell Lung CarcinomaFrance - Active not recruitingPHASE1
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
This study is looking for the right dose of new cancer medicines, durvalumab and tremelimumab, given with or without standard chemotherapy, for advanced solid cancers. It aims to find a dose that helps treat cancer without causing very severe side effects.
For: Solid MalignanciesCanada - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
For: Muscle Invasive Bladder CancerUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
For: Metastatic Breast CancerUnited States · Australia · Brazil - Not yet recruitingPHASE2
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
This study looks at a new way to treat stomach (gastric) and food pipe (oesophageal) cancer. It combines chemotherapy with an immunotherapy drug called durvalumab, given before surgery and again afterwards, to see if it improves patient outcomes.
For: Esophagogastric AdenocarcinomaGermany · Spain - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
For: Hepatocellular CarcinomaUnited States · Australia · Austria - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
This study is looking at a new way to treat a type of liver cancer that can't be removed with surgery. It combines two immunotherapy drugs, durvalumab and tremelimumab, with a radiation treatment called Y-90 SIRT. The aim is to see if this combination is safe and effective.
For: Hepatocellular Carcinoma Non-resectable · HCCGermany - RecruitingPHASE2
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
This study looks at combining targeted heat treatment (radiofrequency ablation or RFA) with chemotherapy and a drug called Durvalumab for a type of bile duct cancer outside the liver. It's for patients whose cancer can't be removed by surgery, aiming to see if this combination works better.
For: Extrahepatic Cholangiocarcinoma · Unresectable Perihilar or Ductal CCAGermany - Active not recruitingPHASE3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study looks at two drugs, durvalumab and tremelimumab, as a first treatment for advanced liver cancer that can't be removed by surgery. Researchers want to see how safe and effective this combination is.
For: Advanced Hepatocellular CarcinomaUnited States · France · Germany - Active not recruitingPHASE1, PHASE2
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
This study is for people with advanced bowel cancer that has spread (metastatic) and is 'microsatellite stable' (MSS). It tests new drug combinations with standard treatment (FOLFOX and bevacizumab) to see if they are safe and work well as a first treatment option.
For: Metastatic Microsatellite-stable Colorectal CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
This study is looking at whether a drug called durvalumab, given after surgery, chemo, and radiotherapy, can help people with bladder cancer. We want to see if it stops the cancer from growing or helps cancer cells die.
For: Bladder CancerCanada · Spain · United Kingdom - Active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
For: Breast CancerUnited States · Belgium · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, open label, single arm, multicentre study on THOracic Radiotherapy in Extensive Stage SCLC patients submitted to first line CHT-RT plus Durvalumab (MEDI4736)
This study is looking at a new way to treat extensive small cell lung cancer. It combines standard chemotherapy with radiotherapy and a drug called Durvalumab. Researchers want to see if this combination can help people live longer without their cancer getting worse.
Italy - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
For: Biliary Tract CancerUnited States · Argentina · Belgium - Active not recruitingPHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
This study looks at new treatments for gynaecological cancers that have come back. It tests a drug called ceralasertib, sometimes with olaparib or durvalumab, to see how well they work in different types of cancer cells, especially those with a specific gene change called ARID1A loss.
For: Gynaecological CancersCanada · United Kingdom - Active not recruitingPHASE2
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
This study looks at a new way to quickly see if a cancer treatment called durvalumab is working for people with oesophageal cancer. We're testing if changes in a blood marker (ctDNA) can tell us sooner than scans if the treatment is helping.
For: Oesophageal CancerUnited Kingdom - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
For: Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
This study is looking at a new treatment called JNJ-90301900 for a type of lung cancer. It combines this new drug with standard chemotherapy, radiation, and another immunotherapy to see if it helps more people get better.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Brazil - RecruitingPHASE1
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
This study looks at combining radiotherapy with new drugs to treat non-small cell lung cancer that hasn't spread widely. Researchers want to find the safest and most effective dose of these new drugs, which help radiotherapy work better by making it harder for cancer cells to repair themselves.
For: Non Small Cell Lung CancerUnited Kingdom - Active not recruitingPHASE2
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
This study looks at new treatments (Ceralasertib alone or with Durvalumab) for people with advanced melanoma that has stopped responding to standard immunotherapy. It aims to see how well they work and if they are safe.
For: MelanomaUnited States · Australia · Belgium - RecruitingPHASE2
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
This study is testing if a new combination of two drugs, Datopotamab Deruxtecan and Durvalumab, works better than Datopotamab Deruxtecan alone for a specific type of advanced triple-negative breast cancer. It focuses on patients whose cancer doesn't have a marker called PDL1.
For: Triple Negative Breast CancerUnited Kingdom - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study looks at new treatments for a type of lung cancer that hasn't spread widely but can't be removed by surgery. It aims to see how well these medicines work and if they are safe after standard initial treatments.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
This study looks at new treatments for endometrial cancer based on specific cancer features. It aims to find better ways to treat patients after surgery, potentially leading to personalised care for different types of endometrial cancer.
For: Endometrial CancerCanada · France · Netherlands - Active not recruitingPHASE3
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
The CompARE trial is testing new treatments for a type of throat cancer called oropharyngeal cancer. It compares different ways of using radiotherapy, surgery, and immunotherapy to see if they improve survival and quality of life for adults with more advanced forms of this cancer.
For: Oropharyngeal CancerIreland · United Kingdom